Abstract

The Biospecimen Core will support the Memorial Sloan Kettering Cancer Center (MSK) SPORE in Lymphoma, which focuses on diffuse large B-cell lymphoma (DLBCL). The overall goal of the Biospecimen core is to provide SPORE investigators with well-characterized biological specimens, including tissues, tissue derivatives, and blood, essential for achieving the aims of the projects. The Biospecimen Core will coordinate tissue acquisition and distribution of high-quality biospecimens by experienced lymphoma pathologists. This shared resource for SPORE investigators will allow for expanding correlative studies, interrogating specific oncogenic signaling pathways, genetic alterations, and biomarker identification.
The Aims of the Biospecimen Core are:
Aim 1. To collect, process, bank, and distribute biospecimens from patients with DLBCL to SPORE investigators and collaborators in support of their research projects.
Aim 2. To provide comprehensive diagnostic characterization of lymphoma specimens collected from patients enrolled on SPORE clinical trials.
Aim 3. To process and perform integral and integrated biomarker analysis on biospecimens collected from patients enrolled on SPORE clinical trials.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA192937-05
Application #
9988851
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2016-08-30
Project End
2021-07-31
Budget Start
2020-08-01
Budget End
2021-07-31
Support Year
5
Fiscal Year
2020
Total Cost
Indirect Cost

  Institution

Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065

  Publications

Lu, Xiaoqing; Fernando, Tharu M; Lossos, Chen et al. (2018) PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival. Blood 132:2026-2039
Kaittanis, Charalambos; Andreou, Chrysafis; Hieronymus, Haley et al. (2018) Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors. J Exp Med 215:159-175
Liu, Yuxuan; Mondello, Patrizia; Erazo, Tatiana et al. (2018) NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death. Proc Natl Acad Sci U S A 115:12034-12039
Intlekofer, Andrew M; Joffe, Erel; Batlevi, Connie L et al. (2018) Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay. Blood Cancer J 8:60
Avanzi, Mauro P; Yeku, Oladapo; Li, Xinghuo et al. (2018) Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System. Cell Rep 23:2130-2141
Pasqualucci, Laura; Dalla-Favera, Riccardo (2018) Genetics of diffuse large B-cell lymphoma. Blood 131:2307-2319
Joshi, Suhasini; Wang, Tai; Araujo, Thaís L S et al. (2018) Adapting to stress - chaperome networks in cancer. Nat Rev Cancer 18:562-575
Kishinevsky, Sarah; Wang, Tai; Rodina, Anna et al. (2018) HSP90-incorporating chaperome networks as biosensor for disease-related pathways in patient-specific midbrain dopamine neurons. Nat Commun 9:4345
Rafiq, Sarwish; Yeku, Oladapo O; Jackson, Hollie J et al. (2018) Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol 36:847-856
Guo, A; Lu, P; Lee, J et al. (2017) HSP90 stabilizes B-cell receptor kinases in a multi-client interactome: PU-H71 induces CLL apoptosis in a cytoprotective microenvironment. Oncogene 36:3441-3449

Showing the most recent 10 out of 28 publications